Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Rituximab 8Cyclophosphamide 7Etoposide 5Prednisone 4Doxorubicin 4Vincristine 3Gemcitabine 3Bendamustine Hydrochloride 3prednylidene 2deltacortene 2Specimen Handling 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2CT-P10 2Busulfan 2venetoclax 1umbralisib 1ublituximab 1tebufenozide 1tafasitamab 1selinexor 1huachansu 1fludarabine phosphate 1epratuzumab 1cc-486 1Whole-Body Irradiation 1Vindesine 1VAP-cyclo protocol 1Thiotepa 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, Large B-Cell, Diffuse × tebufenozide × Clear all
NCT07084662 2025-11-26

Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

Sun Yat-sen University

Phase 2/3 Recruiting
80 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡